GE HealthCare Technologies Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter J. Arduini
- Full Time Employees
- 54,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 500 West Monroe Street Chicago IL United States of America 60661
- IPO Date
- Dec 15, 2022
- CIK
- 0001932393
- Website
- gehealthcare.com
- Similar Companies
- Business
- GE HealthCare Technologies Inc. specializes in the design, production, and global distribution of advanced products, extensive services, and integrated digital platforms aimed at patient diagnostics, therapeutic interventions, and ongoing monitoring across numerous international regions. The organization structures its operations into four distinct divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division delivers sophisticated molecular imaging, computed tomography (CT), magnetic resonance (MR), image-guided therapy, and X-ray systems, alongside specialized offerings for women's health screening. The Ultrasound division offers solutions for the detection, assessment, treatment, and continuous oversight of various conditions through applications in radiology, primary care, cardiovascular health, women’s health, and handheld point-of-care devices, also incorporating surgical visualization and guidance products with AI-enabled productivity tools. The Patient Care Solutions division is dedicated to furnishing medical devices, essential consumables, supportive services, and intelligent digital tools for patient monitoring, anesthesia delivery and respiratory management, diagnostic cardiology, and maternal and infant care. The Pharmaceutical Diagnostics division supplies a range of diagnostic agents, including contrast media for CT, angiography, X-ray, and MR scans, as well as single-photon emission computed tomography and positron emission tomography, to the radiology and nuclear medicine sectors. This segment also provides pharmaceuticals administered prior to imaging to enhance tissue visibility and molecular imaging agents, which are radiopharmaceuticals with radioisotopes used for diagnostic scans. The company was established as a corporate entity in 2022 and maintains its primary corporate offices in Chicago, Illinois. In a significant recent development, the company has agreed to acquire Intelerad, a medical imaging software provider, for $2.3 billion, a move set to substantially enhance its cloud-based and AI-enabled imaging solutions, particularly expanding its reach into outpatient and teleradiology markets. This acquisition is expected to accelerate GE HealthCare's transition to a software-as-a-service (SaaS) business model and significantly boost its recurring revenue.
Company News
GE HealthCare announces cash dividend increase for third quarter of 2026
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
GEHC or SYK: Which Is the Better Value Stock Right Now?
GEHC Launches CareIntellect AI Tool to Optimize Hospital Operations
Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock
GE HealthCare Announces CareIntellect for Operations, Helping Health Systems Optimize Resources and Expand Access to Care
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT/CT, now 510(k) pending with the U.S. FDA
Hsbc Holdings PLC Has $64.22 Million Stake in GE HealthCare Technologies Inc. $GEHC
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach
GEHC vs. HAE: Which Stock Is the Better Value Option?
GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems
GE HealthCare's Photonova™ Spectra gains CE Mark, expanding international access
Why Is GE HealthCare (GEHC) Up 3.6% Since Last Earnings Report?
GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings